drugset / Trial / NCT07038343

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

NCT07038343 ↗

Phase 1/2 Recruiting 480 enrolled Avenzo Therapeutics, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy and potentially in combination therapy to patients with locally advanced or metastatic epithelial solid tumors.

Timeline

Start
2025-06-04
Primary completion
2030-06
Completion
2030-12

Drugs

EvaluationDrugModalityDoseRoute
Subject AVZO-1418 Unknown — Intravenous